Scilex Holding Company Invests $150 Million in Datavault AI
PALO ALTO, Calif. – Scilex Holding Company (Nasdaq: SCLX) has made a bold move by signing an agreement to invest $150 million in Bitcoin into Datavault AI Inc. (Nasdaq: DVLT). This investment is designed to provide growth capital to Datavault, empowering them to enhance their supercomputing infrastructure and expand their data exchange capabilities. This strategic collaboration aims to create new revenue opportunities for both companies.
Positioning Datavault for Growth
Datavault AI has developed a patented platform that is poised to leverage the burgeoning AI market, anticipated to hit $1.8 trillion by 2030. The life sciences analytics market, projected to be worth $35.69 billion by 2024, will continue to grow at an impressive rate of 11.4% CAGR until 2030. By integrating Web 3.0 technologies and blockchain-secured data trading, Datavault delivers solutions that optimize data integrity, trust, and monetization.
A Strategic Vision for Biotech
This strategic investment emphasizes Scilex's intention to capture opportunities in biotech data monetization, which is expected to soar to between $30-$50 billion soon. With extensive experience in the biotech and pharmaceutical fields, Scilex plans to develop a marketplace for Real-World Assets (RWA) that will be tokenized on blockchain systems, thus enabling ownership representation in digital formats.
Details of the Investment Agreement
The purchase agreement entails Scilex receiving up to 278,914,094 shares of Datavault common stock at an effective purchase price of $0.5378 per share. Initially, 15,000,000 shares will be issued, followed by additional shares through a pre-funded warrant, pending stockholder approval from Datavault for excess shares.
Corporate Governance Insights
Datavault’s leadership structure will not be altered substantially as Scilex maintains its right to nominate two directors while holding at least 10% of Datavault's shares. Should their ownership dip below this threshold but still exceed 5%, Scilex will have the right to nominate one director.
Leadership's Vision
Henry Ji, Ph.D., the CEO and Chairman of Scilex, shared insights regarding the motivating factors behind this investment. He expressed confidence that Datavault’s advanced technologies align seamlessly with the pressing needs of the biotech sector for sophisticated data analytics and supercomputing capabilities. "This collaboration underscores our belief in Datavault’s potential to revolutionize markets where precision and trust are paramount,” stated Dr. Ji.
Collaborating for Mutual Growth
Dr. Ji further elaborated that Scilex is committed to supporting Datavault’s mission of maximizing revenue generation while enabling extensive market reach and enhanced operational capacity. Together, these companies expect to harness their resources and expertise to drive significant global impact across various industries.
About Scilex Holding Company
Scilex Holding Company specializes in developing innovative non-opioid products aimed at alleviating acute and chronic pain, as well as addressing neurodegenerative and cardiometabolic diseases. They target unmet medical needs and cultivate market opportunities with a range of non-opioid solutions. Current commercial products include ZTlido® for neuropathic pain, ELYXYB® for migraine treatment, and Gloperba® for gout flares.
Future Developments and Innovations
Moreover, Scilex has multiple product candidates in development, including novel therapies for sciatica and fibromyalgia that position the company for pioneering advancements within the pharmaceutical landscape. These efforts underscore Scilex's dedication to enhancing patient outcomes while meeting diverse medical needs.
About Datavault AI Inc.
Datavault AI is at the forefront of AI-driven data solutions, aiming to monetize assets through their innovative cloud-based platform. Their Acoustic Science and Data Science divisions feature cutting-edge technologies designed to reshape how data is utilized across various industries. The company provides solutions tailored for biotechnology, entertainment, healthcare, and numerous other sectors, focusing on responsible AI practices.
Commitment to Technological Advancement
With patented technologies at its disposal, Datavault is on a path to redefine data valuation and monetization by fostering collaborative environments for secure and immersive data experiences. Their ambitions include crafting bespoke solutions that adapt to the dynamic demands of an evolving market landscape.
Frequently Asked Questions
What is the purpose of Scilex’s investment in Datavault AI?
Scilex’s $150 million investment is aimed at providing growth capital to help Datavault enhance its supercomputing infrastructure and drive revenue growth.
How many shares will Scilex receive from Datavault AI?
Scilex is expected to receive up to 278,914,094 shares of Datavault common stock, including an initial tranche of 15,000,000 shares.
What sectors does Datavault AI aim to serve?
Datavault AI serves multiple sectors including biotechnology, healthcare, entertainment, fintech, and energy, leveraging AI-driven data analytics for enhanced solutions.
What is Scilex's focus in the pharmaceutical industry?
Scilex is focused on developing non-opioid pain management products to improve patient outcomes, targeting significant unmet medical needs in the market.
How does Scilex plan to leverage its expertise?
Scilex plans to use its deep expertise in biotech to create a marketplace for tokenized Real-World Assets (RWA), enhancing revenue generation opportunities in the industry.
